X. Wang
Pfizer (United States)(US)
Publications by Year
Research Areas
Pharmacogenetics and Drug Metabolism, Alzheimer's disease research and treatments, Cancer Immunotherapy and Biomarkers, Diabetes Treatment and Management, Metabolism, Diabetes, and Cancer
Most-Cited Works
- → Dose‐ranging efficacy and safety study of ertugliflozin, a sodium‐glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin(2015)65 cited
- → Blood pressure‐lowering effect of the sodium glucose co‐transporter‐2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension(2015)60 cited
- → Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab(2018)38 cited
- → Tofacitinib pharmacokinetics in children and adolescents with juvenile idiopathic arthritis(2024)6 cited
- → Target promiscuity and physicochemical properties contribute to pharmacologically induced ER-stress(2012)4 cited
- → Pharmacodynamic (PD) changes in tumors and peripheral blood T cell receptor (TCR) repertoire in a phase I study combining OX40 (PF-04518600) and 4-1BB (utomilumab) agonistic monoclonal antibodies (mAbs)(2018)3 cited
- → Meta‐Analysis of Noncompartmental Pharmacokinetic Parameters to Evaluate the Impact of CYP2C19 and CYP2C9 Genetic Polymorphisms on Abrocitinib Exposure(2024)3 cited
- → Assessment of the Effects of Abrocitinib on the Pharmacokinetics of Probe Substrates of Cytochrome P450 1A2, 2B6 and 2C19 Enzymes and Hormonal Oral Contraceptives in Healthy Individuals(2024)3 cited
- → Safety and clinical activity of subcutaneously (SC) administered anti-PD-1 antibody PF-06801591 in phase I dose-expansion cohorts of locally advanced or metastatic non-small cell lung cancer (NSCLC) and urothelial carcinoma (UC)(2019)1 cited
- → FRI0465 TOFACITINIB POPULATION PHARMACOKINETICS IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS: A POOLED ANALYSIS OF DATA FROM THREE CLINICAL STUDIES(2020)1 cited